Exploratory analysis of serial pan-immune-inflammation value and its early dynamics during neoadjuvant chemotherapy as a predictor of complete cytoreduction at interval debulking surgery in advanced ovarian cancer: a retrospective cohort study
A simple blood inflammatory marker measured during chemotherapy may predict which ovarian cancer patients will achieve optimal surgical outcomes.
This retrospective cohort study from a major Chinese gynecologic oncology center evaluated whether pan-immune-inflammation value (a composite blood-based inflammatory index) measured serially during NACT can predict surgical cytoreduction success in advanced ovarian cancer. Predictive ability for complete cytoreduction would have direct clinical implications for surgical planning and treatment optimization.
What the study was
- Study design
- Retrospective cohort study (Peking Union Medical College Hospital)
- Population
- Patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy and interval debulking surgery
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- World Journal of Surgical Oncology
Why it surfaced
Blood-based inflammatory indices as surgical outcome predictors are an emerging area; retrospective design limits causal inference; abstract not fully retrieved so confidence is medium.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.